The non-profit that writes the clinical trial data standards (SDTM, ADaM, CDASH) that FDA, PMDA and NMPA require for every cancer drug submission.
Founded in 1997, CDISC develops open, global standards for collecting, structuring and submitting clinical research data. Its Study Data Tabulation Model and Analysis Data Model are mandatory for new drug applications to the US FDA and Japan's PMDA and accepted by China's NMPA, and its Controlled Terminology, CDASH data collection standards and Therapeutic Area User Guides (including for breast, prostate and lung cancer and for oncology endpoints such as RECIST) make trial data comparable across sponsors. CDISC standards underpin data sharing platforms such as Vivli and Project Data Sphere and the pooled analyses that regulators and academics run on legacy oncology trials. It works with HL7 on mapping trial standards to FHIR healthcare data.
Shares Pharmaceuticals and Medical Devices Agency, National Medical Products Administration / Center for Drug Evaluation, FDA Oncology Center of Excellence, Regulatory divergence between regions.
Shares HL7 International, Data silos.
Shares National Medical Products Administration / Center for Drug Evaluation, Regulatory divergence between regions, Data silos.
Shares National Medical Products Administration / Center for Drug Evaluation, Regulatory divergence between regions, Data silos.
Shares Real-world evidence, Regulatory divergence between regions.
Shares RECIST, Real-world evidence.
Shares Real-world evidence, Regulatory divergence between regions.